All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

ASH Congress 2022

Share:

Dec 10, 2022

X post image

1 Apr 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @BrunoPaiva_UNAV, University of Navarra, Pamplona, ES. We asked, What is BloodFlow and how can it improve MRD assessment in MM?

Watch the full interview here 👇
#mmsm #myeloma
https://t.co/XrRWWi7fol

X post image

31 Mar 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, @myelomaMD, @MayoClinic. We asked, How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy?

Watch the interview here 👇
#mmsm #myeloma
https://t.co/xXmwKdcpMd

X post image

4 Mar 2023

#ASH22 | 🎥 The Multiple Myeloma Hub was pleased to speak to @bdermanmd, @UChicago. We asked, What are the main improvements in next-generation CAR T-cell products?

Watch the full video here 👇
#myeloma #mmsm #CARTcell
https://t.co/V6MBVNMSTP

X post image

3 Mar 2023

#ASH22 | 🎥 The Multiple Myeloma Hub was pleased to speak to @BrunoPaiva_UNAV, University of Navarra, Pamplona, ES. We asked, What is BloodFlow and how can it improve MRD assessment in MM?

Watch the full interview here 👇
#mmsm #myeloma
https://t.co/XrRWWi7fol

X post image

1 Mar 2023

#ASH22 | The latest data on GPRC5D-directed CAR T-cell and bispecific antibodies for patients with #multiplemyeloma were presented at ASH 2022.

Check out our summary here.
👉 https://t.co/3mxJ8Z3VWh

#mmsm #myeloma

X post image

28 Feb 2023

#ASH22 | 🎥 The Multiple Myeloma Hub was pleased to speak to @moriegertz, Mayo Clinic, Rochester, US. We asked, How to treat patients with AL amyloidosis relapsing from Dara-CyBorD?

Watch the full video here 👇
#myeloma #mmsm
https://t.co/ciTG1PrMg5

X post image

25 Feb 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @bdermanmd, @UChicago. We asked, After ASH 2022, are we closer to using MRD-guided treatment decisions in MM?

Watch the full video here 👇
#myeloma #mmsm
https://t.co/yKoplZFBvn

X post image

22 Feb 2023

#ASH22 | 🎥 The Multiple Myeloma Hub was pleased to speak to @MorieGertz, Mayo Clinic, Rochester, US. We asked, Is birtamimab an option for patients with advanced AL amyloidosis at high risk for early death?

Watch the full video here 👇

#myeloma #mmsm
https://t.co/lqUPZxV6Ja

X post image

21 Feb 2023

#ASH22 | Updates from the MonumenTAL 1 trial of talquetamab in patients with R/R MM were presented at by @AjaiChari.

Read more about the recent findings and future trials planned here 👉 https://t.co/X5ARolhC81

#mutliplemyeloma #mmsm

X post image

13 Feb 2023

#ASH22 | Review the latest smoldering MM treatment recommendations and developments presented at ASH 2022.

Read more here 👉 https://t.co/IBaA9mFY0s

#MM #MMSM

X post image

9 Feb 2023

🎧 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @TMSchmidtMD, University of Wisconsin-Madison. We asked, How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?

Listen to the interview here 👉 https://t.co/FsFhIv6tLf

#mmsm

X post image

8 Feb 2023

#ASH22 | Want to find out more about development and in vitro and in vivo evaluation of a novel bispecific T-cell engager targeting ILT3 for the treatment of MM?
Read more here 👉 https://t.co/0Kd6V6i2pT
#mm #myeloma

X post image

6 Feb 2023

#ASH22 | @dra_v_hungria, Clínica São Germano, São Paolo, BR, presents on the discrepancies between #multiplemyeloma treatment centers in Brazil.

Listen to the podcast and read our summary here.
👉 https://t.co/fZOl0o5kR9

#mmsm #myeloma

X post image

3 Feb 2023

🎧 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @mbeksac56, Ankara University. Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients with extramedullary disease?
Listen to the interview here 👉 https://t.co/7DVKMdByr7
#mmsm #myeloma

X post image

30 Jan 2023

#ASH22 | Want to know more about the efficacy and safety of daratumumab and lenalidomide, without dexamethasone, for the treatment of NDMM in frail patients?
Read more about the IFM 2017-03 clinical trial here.
👉 https://t.co/nNFOwZKzjW

#mmsm #myeloma

X post image

27 Jan 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @HiraSMian, @McMasterU. We asked, Why should frailty be considered a dynamic factor in MM and when should it be assessed?

Watch the full video here 👇
#mmsm #myeloma
https://t.co/bbS8ZpT7qi

X post image

20 Jan 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @BrunoPaiva_UNAV, @CIMA_unav. We asked, How can we identify early the best responders to ide-cel?

Watch the full video here 👇
#mmsm #myeloma
https://t.co/R4WOqH2k8k

X post image

13 Jan 2023

Findings presented at #ASH22 suggest the need for a change in the dietary standard of care for patients with neutropenia following stem cell transplantation. We summarize the key findings from the NEUTRODIET trial.

#GvHDsm #mmsm #bmtsm
https://t.co/4Z0Q81GO4d

X post image

12 Jan 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, @myelomaMD, @MayoClinic. We asked, How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy?

Watch the interview here 👇
#mmsm #myeloma
https://t.co/VMy3mdRrZN

X post image

6 Jan 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @BrunoPaiva_UNAV, University of Navarra, Pamplona, ES. We asked, What is BloodFlow and how can it improve MRD assessment in MM?

Watch the full interview here 👇
#mmsm #myeloma
https://t.co/0o3KdzCvjd

X post image

3 Jan 2023

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @bdermanmd, @UChicago. We asked, What are the main improvements in next-generation CAR T-cell products?

Watch the full video here 👇
#myeloma #mmsm #CARTcell
https://t.co/zM7W78MlHo

X post image

27 Dec 2022

#ASH22 | 🎥 The Multiple Myeloma Hub was pleased to speak to @moriegertz, Mayo Clinic, Rochester, US. We asked, How to treat patients with AL amyloidosis relapsing from Dara-CyBorD?

Watch the full video here 👇
#myeloma #mmsm
https://t.co/sIgvPbkjRP

X post image

21 Dec 2022

🎥 #ASH22 | The Multiple Myeloma Hub was pleased to speak to @bdermanmd, @UChicago. We asked, After ASH 2022, are we closer to using MRD-guided treatment decisions in MM?

Watch the full video here 👇
#myeloma #mmsm
https://t.co/G56Ilw93Ja

X post image

15 Dec 2022

#ASH22 | 🎥 The Multiple Myeloma Hub was pleased to speak to @MorieGertz, Mayo Clinic, Rochester, US. We asked, Is birtamimab an option for patients with advanced AL amyloidosis at high risk for early death?

Watch the full video here 👇

#myeloma #mmsm
https://t.co/BncscFkFPM

X post image

14 Dec 2022

We hope you enjoyed following our live updates and congress coverage from #ASH22!

Keep an eye on our socials for post-congress key points and insights!

#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #leusm #allsm

X post image

13 Dec 2022

RT @MPN_Hub: CONGRESS | #ASH22
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRN…

X post image

13 Dec 2022

CONGRESS | #ASH22 https://t.co/kyF5UsEhRg

X post image

13 Dec 2022

CONGRESS | #ASH22
Abstract 157: 'Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with RRMM: Phase 1/2 Results from MonumenTAL-1', presented by @AjaiChari has been selected as one of the Best of ASH.
#mmsm #myeloma

X post image

13 Dec 2022

CONGRESS | #ASH22
Abstract 98: 'Tumour-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in MM and Premalignant Plasma Cell Disorders' presented by @Hope34Me has been selected as one of the Best of ASH in the theme: Niche and Microenvironment.
#mmsm

X post image

13 Dec 2022

CONGRESS | #ASH22
Abstract 860: 'Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumour Heterogeneity and Treatment Outcome' presented by @Simontuk was selected as one of the Best of ASH for the theme of: Niche & Microenvironment
#myeloma #mmsm

X post image

13 Dec 2022

CONGRESS | #ASH22
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune response and implications for the immunocompromised, discussing the role germinal centers play in immunity.

X post image

13 Dec 2022

CONGRESS | #ASH22
@bhwords of the @GSTTnhs discusses thrombosis and coagulopathy including immune-mediated thrombocytopenia and thrombosis following COVID-19 vaccination, emphasising the need for increased awareness for VTE.

X post image

13 Dec 2022

CONGRESS #ASH22 | @SurbhiSidanaMD @StanfordMed discusses idel-cel for patients with R/R multiple #Myeloma with renal insufficiency. CRS, neurotoxicity & NRM were comparable between pts with or without renal insufficiency. Efficacy was similar between the 2 groups. N=211 #mmSM

X post image

13 Dec 2022

#ASH22 @kordeneha1 from @MSKCancerCenter presents data on patients with sustained MRD negativity 3 years after the cessation of lenalidomide based maintenance treatment for MM, exploring the durability of remission #myeloma

X post image

13 Dec 2022

#ASH22 @HiraSMian from @McMasterU presents an interim analysis and data from the prospective MFRAIL clinical study, evaluating the association of frailty assessments at at baseline and longitudinally with clinical outcomes in patients with MM #mmsm #MYELOMA

X post image

13 Dec 2022

#ASH22 @SunilLakhwani9 from Hospital Universitaria de Canarias reveals that on multivariate analysis both MRD and IP recovery have independent prognostic value for PFS. Recovery of IP after non-continuous treatment in elderly patients with CR or VGPR confers better PFS and OS

X post image

13 Dec 2022

#ASH22 @bdermanmd from @UChicago: data from the prospective MRD2STOP (NCT04108624) clinical trial, investigating maintained MRD-negativity in patients who discontinue maintenance therapy #mmsm #myeloma

X post image

13 Dec 2022

#ASH22 @BrunoPaiva_UNAV from @CIMA_unav presented work exploring the prognostic value of the depth of serological and MRD response in patients with MM, after CAR T cell therapy. A KaRMMA trial update #myeloma

X post image

13 Dec 2022

#ASH22 @SunilLakhwani9 from Hospital Universitaria de Canarias presents work to evaluate the prognostic value of the recovery of heavy/light chair pairs to predict PFS in patients with transplant-eligible NDMM in receiving intensive continuous treatment #MMSM #myeloma

X post image

13 Dec 2022

#ASH22 Laura Notarfranchi
@_pethema
discusses peripheral blood MRD vs bone marrow MRD, with negative predictive value <70%. Here she presents work to develop a technique with increased peripheral MRD sensitivity in patients from the GEM2014MAIN clinical trial

X post image

13 Dec 2022

#ASH22
Christopher Ferreri from @MDAndersonNews discusses the tolerability of ide-cel for patients with RRMM and outcomes with prior therapy

X post image

13 Dec 2022

#ASH22
Kwee Yong from @uclcancer discusses the UK-MRA RADAR phase II/III trial recruiting NDMM patients eligible for ASCT, with eligible patients receiving 4 cycles of RCyBorD #mmsm #myeloma

X post image

13 Dec 2022

CONGRESS #ASH22
Katja Weisel from University Cancer Centre Hamburg concludes: Isa-KRd in induction and consolidation leads to high MRD negativity rates after consolidation in high-risk NDMM. No new safety signals were indentified

X post image

13 Dec 2022

#ASH22 John Jones from @ICR_London presents data from the phase II Myeloma XI. SPM incidence was rare, but higher in patients treated with lenalidomide at both induction and maintenance compared to single exposure or no exposure #mmsm #myeloma

X post image

13 Dec 2022

#ASH22 @TomBmt133 @UofCalifornia presents the final PFS analysis of the Phase 3 IKEMA study (NCT03275285) confirming improved PFS compared with Kd in RRMM. Grade ≥3 and serious TEAE were similar in both arms in early relapse, but higher in the Isa-Kd arm in late relapse #mmsm

X post image

13 Dec 2022

CONGRESS l #ASH22
@CarlynRTanMD @MSKCC presents a retrospective analysis of patients treated with Vrd/KRd for NDMM. KRd induction and R-ISS- I:R-ISS-II Stage II were associated with better PFS. Induction regimens in early transplant-eligible patients can be tailored #mmsm

X post image

13 Dec 2022

CONGRESS l #ASH22
Sara Bringhen from Univseritaria di Torino discusses the phase IV NCT0382929371 trial, comparing bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) transplant-ineligible NDMM patients. No safety concerns reported. 50% patients were frail

X post image

13 Dec 2022

CONGRESS | #ASH22
Christine Chen reported that medical benefit, safety/ risk of complications, psychosocial factors, and medical urgency were identified by a CAR T-cell therapy Ethics Working Group as being key themes. Tools were then developed to aid prioritization.
#mmsm

X post image

13 Dec 2022

CONGRESS | #ASH22
Christine Chen, Princess Margaret Cancer Centre, explained the need for an ethical framework and priority setting-process for allocating CAR T-cell therapy.
#mmsm #Lymsm

X post image

12 Dec 2022

#ASH22| @bdermanmd @UChicago presents results from a prospective trial of multi modal MRD negativity to guide discontinuation of maintenance therapy in MM. There were high rates of sustained MRD -ve and lack of disease progression #MultipleMyeloma #mmsm #medicalcongress

X post image

12 Dec 2022

#ASH22| Jan Eckman @RocheDia gives a talk on a novel 2:1 GPRC5D T cell bi specific Ab which shows best in class potential for the treatment of MM as both a mono therapy and in combination #MultipleMyeloma #mmsm #medicalcongress

X post image

12 Dec 2022

#ASH22| @BrunoPaiva_UNAV @ClinicaNavarra discusses early and sustained undetectable MRD after ide-cel is associated with prolonged PFS and highlights the prognostic implication of different serological and MRD response dynamics #myeloma #mmsm #medicalcongress

X post image

12 Dec 2022

#ASH22| @SunilLakhwani @ULL discusses the potential prognostic factor of uninvolved heavy/light chain pair immunoparesis during maintenance in MM, which in turn could complement the value of standard MRD. #myeloma #mmsm #medicalcongress

X post image

12 Dec 2022

#ASH22| Laura Notarfranchi @unipr discusses ultra sensitive MRD assessment in PB using the blood flow of pts with MM. She highlights achieving unprecedented sensitivity levels down to 10-8 in the proposed BloodFlow model. #myeloma #mmsm #medicalcongress

X post image

11 Dec 2022

CONGRESS l #ASH22
@Davine_HB from @ErasmusMC concludes that PCL-like status is and independent risk-factor for high risk MM, and concurrent PCL-like MM and R2-ISS IV staging may represent exceptionally high-risk NDMM. CTC can be detected in 90% of new patients #MMSM #myeloma

X post image

11 Dec 2022

CONGRESS l #ASH22
@Davine_HB from @ErasmusMC presents describes that PCL-like status is associated with inferior PFS and OS. Prognostic significance was maintained in multivariate modelling, and combined with R2-ISS classification

X post image

11 Dec 2022

CONGRESS l #ASH22
@Davine_HB from @ErasmusMC presents data from research on combining PCL-like status with the R2-ISS classification to improve prognostic accuracy and risk stratification in patients with NDMM. Data from 525 patients with NDMM was included #mmsm #myeloma

X post image

11 Dec 2022

CONGRESS l #ASH22
@MyMKaiser from @royalmarsden concludes that the cross cohort meta-analysis demonstrates that extended genetic profiling including gain(1q), t(4;14) and del(17p) for all patients and single/double hit analysis can improve risk-stratification in NDMM and RRM

X post image

11 Dec 2022

CONGRESS l #ASH22
@MyMKaiser from @royalmarsden describes single and double hit mutations, with reduced OS in double hit patients. The results were consistent across data sets

X post image

11 Dec 2022

CONGRESS l #ASH22
@MyMKaiser from @royalmarsden presents gives his expert opinion on genetic profiling for outcome prediction in NDMM. Using gain(1q), t(4;14) and del(17p) as a core set, genetic data from 17 prospective RCT and 6041 extended genetic patient profiles

X post image

11 Dec 2022

CONGRESS l #ASH22
@FrancescoMaura4 presents on behalf of Anthony Cirrincione from @SylvesterCancer - pre-gain deletions seen in MM can involve oncogenes such as ATM, BIRC3, USP8 and TCF3. Both hyperdiploidy and t(11;14) anomalies can be preceded by earlier driver events

X post image

11 Dec 2022

CONGRESS l #ASH22
@FrancescoMaura4 presents on behalf of Anthony Cirrincione from @SylvesterCancer, detailing the latest evidence on tracking the genomic events that underly MM through clonal evolution, including key events such as hyperdiploidy and immunoglobulin translocations

X post image

11 Dec 2022

#ASH22| @_DrCP @royalmarsdenNHS presents data from the #Myeloma XI trial investigating the optimal duration of lenalidomide maintenance after SCT. She highlights maintenance beyond 4-5 yrs was associated with improved PFS in the overall patient population #medicalcongress #mmsm

X post image

11 Dec 2022

#ASH22| Salomon Manier, Lille University Hospital presents safety and efficacy data from the phase 3 IFM2017-03 trial investigating a dexamethasone sparing-regimen in combination with daratumumab and lenalidomide in frail patients #myeloma #mmsm #medicalcongress

X post image

11 Dec 2022

#ASH22| Paul Richardson @DanaFarber presents results from the dose expansion phase of the phase 1/2 trial investigating mezigdomide in combo with dexamethasone for pts with r/r MM.The ORR was 40.6%, and the median duration of response at 7.3 months #myeloma #mmsm #medicalcongress

X post image

11 Dec 2022

#ASH22| Suzanne Trudel @pmcancercentre discusses the use of pretreatment of tocilizumab prior to cevostamab to reduce severity and incidence of CRS in. She highlights 90.9% of pts experienced CRS who had no pretreatment compared to 38.7% who did #myeloma #mmsm #medicalcongress

X post image

11 Dec 2022

#ASH22| @End_myeloma @uabmedicine presents results from the phase 1 study of BCMA CAR-T cell therapy BMS-986354 in pts with r/r MM. He highlights 98.1% of pts with objective response rate and 57.4% with a very good partial response or better #myeloma #mmsm #medicalcongress

X post image

11 Dec 2022

#ASH22| Dan Vogl @PennCancer presents results from the first-in-human phase 1/2 study of Modakafusp Alfa in pts with r/r MM. Encouraging therapeutic activity was seen at 1.5mg/kg QW4 and a phase 2 trial to define single agent dosing is currently enrolling #mmsm #medicalcongress

X post image

11 Dec 2022

Keep an eye on our Twitter page!

The @MM_Hub will be covering the following session(s) today:

-Novel Drugs and Optimized Approaches in Myeloma

Stay tuned for live updates, key insights, and interview coverage!

#ASH22 #hematology #medicalcongress #cancerresearch #mmsm

X post image

11 Dec 2022

RT @Mohty_EBMT: Let’s spread the word to the world at #ASH22 @ASH_hematology @ASHClinicalNews @TheIACH @TheEBMT_PAC @CLLAdvocates @AML_Hub…

X post image

11 Dec 2022

CONGRESS l #ASH22
Juan Du from the Changzheng Myeloma Center describes no Grade 3 or above ICANS or CRS. CAR-T cell expansion was good in all patients. FasTCAR-T produced CAR-T cells promises favourable efficacy and safety

X post image

11 Dec 2022

CONGRESS l #ASH22
Juan Du from Changzheng Myeloma Center - median time to 1st response was 1 month. At median follow-up 8 months in 16%, ORR=100% with 88% MRD-ve, with all patients VGPR or better #mmsm

X post image

11 Dec 2022

CONGRESS l #ASH22
Juan Du from the Changzheng Myeloma and Lymphoma Center presents data from the phase I GC012F trial (NCT04935580), with CAR-T cells produced on the FasTCAR-T manufacturing platform for the treatment of high-risk patients with NDMM who are transplant eligible

X post image

10 Dec 2022

CONGRESS l #ASH22
@DrKrinaPatel @MDAndersonNews- ide-cel achieves deep responses in patients with MM who relapse after frontline after ASCT. With CRS and NT similar to patients receiving ide-cel in later lines, the clinical benefit-risk profile in favourable early line

X post image

10 Dec 2022

CONGRESS l #ASH22
@DrKrinaPatel @MDAndersonNews Grade 3 or more AE occurred in all patients, including neutropenia (94.6%) and thrombocytopaenia (37.8%). Cell expansion was good, with higher ide-cel levels CR or better

X post image

10 Dec 2022

CONGRESS l #ASH22
@DrKrinaPatel @MDAndersonNews provides an update from the KarMMA-2 Trial – Cohort 2a, on the efficacy and safety of ide-cel for clinical high-risk MM, with 37 patients treated after early relapse. At median follow-up of 21.5 months, CRR=45.9% and ORR =83.8%

X post image

10 Dec 2022

#ASH22
Francesco Di Meo, @IUMedSchool describes a novel ILT3 targeted bi-specific T-cell engager, with high in vitro/vivo model anti-tumour activity. Murine models demonstrated reduced MM burden and increased survival. ILT3 is a potential MM treatment target

X post image

10 Dec 2022

RT @RahulBanerjeeMD: Excited to see orphan GPRC5D adopted by all of us at #ASH22!

@BerdejaJesus presented BMS-986393 (CAR-T, not bsAb). Gr…

X post image

10 Dec 2022

CONGRESS l #ASH22
Lauren Peres @MoffitResearch concludes - in the SOC setting 70% of patients identified as Non-Hispanic White, 17% Non-Hispanic Black and 10% Hispanic. Non-Hispanic Black patients had more any grade CRS (97%) and longer hospital stay (median 12.5 days) #mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
Lauren Peres from @MoffitResearch describes that median prior LOT before ide-cel was 6 (range, 3-19) in the SOC setting. Maximum ORR was 84%, with CR or better in 34% of patients. No racial/ethnic differences were observed in OS #mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
Lauren Peres, @MoffitResearch describes racial and ethic differences in treatment outcomes of RRMM patients treated with SOC ide-cel. Presenting data from 215 patients, it was found 34% had high risk cytogenetics, and that 43% were penta-refractory #mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Hira Mian @HiraSMian, @McMasterU discusses fluctuating frailty in older adults with MM. Current frailty status appeared a better predictor of OS than frailty status at diagnosis, suggesting value in remeasuring over time to provide tailored treatment.
#mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
@Kevin_Reyes650 @UCSFMedcine
The presence of 1q copy number gain was associated with inferior median OS of 24.8 months (not reached for those without). Patients may respond to treatments thought refractory prior to CAR-T treatment, but with limited DOR #mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
@Kevin_Reyes650 from @UCSFMedcine presents the latest findings from a retrospective, single-centre analysis of patients with RRMM progressing after CAR-T treatment. Data from 78 patients identified a 2-year PFS of 34.6% and 2-year OS of 13 months #mmsm

X post image

10 Dec 2022

RT @eliaseythorsson: Just finished presenting an oral abstract at #ASH22 detailing a prediction model that predicts the probability of ≥10%…

X post image

10 Dec 2022

CONGRESS | #ASH22
Federico Stella, @LaStatale, concludes that a restrictive diet is therefore an unnecessary burden on patients’ quality of life. #mmsm #GvHD

X post image

10 Dec 2022

CONGRESS | #ASH22
Federico Stella, @LaStatale¸ describes similar infection rates, nutritional outcomes, and acute GvHD incidence between patients on a Protective Diet (n = 111) or a Non-Restrictive Diet (n = 111) post-HSCT in the NEUTRODIET trial.
#mmsm #GvHD

X post image

10 Dec 2022

CONGRESS l #ASH22
@SantiagoThibaud @TischCancer describes that count recovery was mostly achieved, cytopenia persisting at 1 year in <10%. Older age, more prior therapies, and 2 or more previous ASCT were significantly associated with poor count recovery 4 months after infusion

X post image

10 Dec 2022

CONGRESS l #ASH22
@SantiagoThibaud @TischCancer presents a data on prolonged cytopaenias and count recovery in CAR-T treated patients with RRMM . Data from 90 patients with ≥Grade 3 cytopenias included 28%/7% of patients at day 120/360 respectively

X post image

10 Dec 2022

CONGRESS l #ASH22
Daniel Lowther describes detectable BCMA levels in 98%/98.9% of patients in DREAMM-1/DREAMM-2 at progression. No evidence suggests BCMA expression is completely lost after treatment with Belantamab mafodotin, or total lymphocyte count negatively affected #mmsm

X post image

10 Dec 2022

RT @RahulBanerjeeMD: 🚨 Super important #ASH22 slide - based on patient & caregiver interviews, what actually needs to happen with #MMsm car…

X post image

10 Dec 2022

CONGRESS | #ASH22
Sandy Wong @SandyWong02111, @UCSFCancer reports phase I data for the 2+1 BCMAxCD3 T-cell engager alnuctamab. In heavily pretreated RRMM, SC alnuctamab ORR = 53% & median time to response = 1 month. SC improved safety profile vs IV, allowing higher doses. #mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Carmelo Carlo-Stella, @HUNIMED reports phase I data for RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody with 2:1 configuration. High anti-MM activity was seen: ORR 71.4% for IV & 63.6% for SC routes. CRS occurred at 82.4% for IV & 78.9% for SC. #mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Emma Searle @DrEmmaSearle describes ORR = 93.5%, with 81% of patients progression-free at data cut-off. CRS was the most common non-hematologic AE (any-grade = 81.3%), with no ICANS events. #mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Emma Searle @DrEmmaSearle, @OfficialUoM presents initial data from the ongoing phase Ib MajesTEC-2 trial, showing that the addition of teclistamab to daratumumab and lenalidomide is well tolerated and shows promising clinical activity in patients with MM. #mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Nizar Bahlis @NBahlis adds that 56.3% patients experienced any-grade CRS with elranatamab in MagnetisMM-3, mitigated by the step-up priming regimen.
#mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Nizar Bahlis @NBahlis, @UCalgary presents phase II MagnetisMM-3 trial of elranatamab in triple-class and penta-drug RRMM, naïve to BCMA-targeted therapy. ORR by BICR = 61%, with 84.4% patients achieving 9-month DOR.
#mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
Daniel Lowther reveals that at progression, BCMA levels were detectable in 98% of patients in DREAMM-1 and 98.9% of patients in DREAMM-2. No evidence was found to suggest that BCMA expression is completely lost after treatment with Belantamab mafodotin

X post image

10 Dec 2022

CONGRESS l #ASH22
@mvmateos from @hpsalamanca discusses findings from the GEM-CESAR trial for SMM. At 70 months, 94% of patients have not progressed to MM, with biochemical progression in 48% of patients #mmsm #myeloma

X post image

10 Dec 2022

CONGRESS l #ASH22
@eliaseythorsson from @Landspitali explains how the model uses laboratory tests routinely performed in early MGUS work-ups to determine if BM sampling can be deferred in low risk patients. The model still needs external validation #myeloma #mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
@eliaseythorsson from @Landspitali discusses upfront bone marrow sampling in patients with MGUS, with data from the prospective Istopmm cohort study. With 1,013 patients, a model to prospectively predict the risk of ≥10% BMPC in MGUS patients was validated

X post image

10 Dec 2022

CONGRESS | #ASH22
Ajai Chari @AjaiChari further detailed that in hard-to-treat patients exposed to prior T-cell redirection therapy, ORR with talquetamab was 62.7%, with a similar safety profile to patients naive to T-cell redirection therapy.
#mmsm

X post image

10 Dec 2022

CONGRESS | #ASH22
Ajai Chari @AjaiChari, @IcahnMountSinai describes phase II results from the MonumenTAL-1 trial of SC talquetamab in RRMM. ORR was 74.1% at 0.4 mg/kg QW dose (n=106/143), and 73.1% at 0.8 mg/kg Q2W dose (n=106/145). CRS was the most common AE at both doses. #mmsm

X post image

10 Dec 2022

CONGRESS l #ASH22
@camilagdeblois @ClinicaNavarra describes how transcriptional stability is seen during induction with genomic divergence, and clonal evolution after HSCT. Using drugs with alternative modes of action maybe required to overcome MRD resistance after induction

X post image

10 Dec 2022

CONGRESS l #ASH22
Diana Cortes-Selva concludes data from the MajesTEC-1 Trial. Longer PFS is seen in patients with lower PD-1+/CD8 cells in peripheral blood and lower frequency of CD25+ or CD38+/CD4 T-cells in bone marrow #mmsm #myeloma

X post image

10 Dec 2022

CONGRESS l #ASH22
Diana Cortes-Selva reveals non-responders demonstrate unfavorable baseline immune characteristics, including lower T-cell counts and higher PD-1, TIM-3, and CD38 expressing T-cell counts. Higher BCMA levels are seen with extramedullary and higher R-ISS disease

X post image

10 Dec 2022

CONGRESS l #ASH22
Diana Cortes-Selva presents translational outcomes and data re: teclistamab from the Phase I/II MajesTEC-1 study. Baseline expression of BCMA on bone marrow plasma cells is prevalent and highly variable in RRMM, but not associated with clinical responses

X post image

10 Dec 2022

CONGRESS | #ASH22
Hamza Hashmi @hamzahashmi87, @muschollings presents real world data suggesting the presence of 2 of either prior BCMA-directed exposure, high-risk cytogenetics, or raised ferritin after lymphodepletion negatively impacts survival after Ide-cel therapy.
#mmsm

X post image

10 Dec 2022

RT @HadidiSamer: #ASH22 #mmsm Oral- Dr Straka
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Len/Dex with Len/Dex…

X post image

9 Dec 2022

The @MM_Hub will be covering the 64th ASH Annual Meeting & Exposition!

🗓 Date: Dec 10–13
📍 Location: New Orleans and online

Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance!

#ASH22 #mmsm

X post image

1 Dec 2022

Get ready for #ASH22 with us! 

The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @mm_hub!

📌 https://t.co/KzCux0yBCr

#ASH2022 #mmsm #medicalabstracts #cancer #cancerresearch

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASH 2022 American Society of Hematology

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox